With the aim to provide evidence for the relative cardiovascular safety of GnRH agonists and antagonists, the PRONOUNCE study prospectively compared major adverse cardiovascular events (MACE) in prostate cancer patients with preexisting atherosclerotic CVD randomized to receive GnRH agonists versus GnRH antagonists. Here, GNRH1 is linked to prostate carcinoma.